Mantle Cell Lymphoma

Latest News

Latest Videos

Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCL

Mitchell R. Smith, MD, PhD, of the GW Cancer Center

Dr. Smith on the Rationale of the ECOG-ACRIN E1411 Trial in MCL

Peter Martin, MD, of Weill Cornell Medicine

Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL

Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

Tycel Jovelle Phillips, MD, of Rogel Cancer Center

Dr. Phillips on the Next Steps With Venetoclax/Lenalidomide/Rituximab in MCL

Dr. Martin on the Findings of a Real-World Analysis of Outcomes in MCL

Tycel Jovelle Phillips, MD, a clinical associate professor, Division of Hematology and Oncology, Department of Internal Medicine at Rogel Cancer Center, Michigan Medicine

Dr. Philips on the Design of a Phase 1 Trial With Venetoclax/Lenalidomide/Rituximab in MCL

Narendranath Epperla, MD, MS, a hematologist specializing in the treatment of Hodgkin and non-Hodgkin lymphomas at The Ohio State University Comprehensive Cancer Center—James

Dr. Epperla on the Efficacy of Brexucabtagene Autoleucel in MCL

Dr. Martin on the Rationale to Evaluate Real-World Outcomes in MCL

Dr. Epperla on Future Research Efforts in MCL

CME Content

Virtual Event

Minnesota Society of Clinical Oncology

2 Sessions are Available!

Virtual Event

South Carolina Oncology Society

2 Sessions are Available!

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Virtual Event

Washington State Medical Oncology Society

1 Session is Available!

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Virtual Event

Arkansas Association of Cancer Professionals

2 Sessions are Available!

Virtual Event

North Carolina Oncology Association

2 Sessions are Available!

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Video

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Multimedia

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Multimedia

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Multimedia

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

Video

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Video

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Video

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Video

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD

Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Video

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Video

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Multimedia

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Video

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Video

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

More News

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

BySonali M. Smith, MD

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Precision Medicine: The Next Paradigm Shift in MCL

ByCaroline Seymour

May 17th 2020

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

Dr. Wang on Research Trends in MCL

ByLuhua (Michael) Wang, MD

May 15th 2020

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Dr. Zelenetz on Progress Made in MCL Treatment

ByAndrew D. Zelenetz, MD, PhD

May 14th 2020

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Dr. Zelenetz on Progress Made in MCL Treatment

ByAndrew D. Zelenetz, MD, PhD

May 14th 2020

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Dr. Wang on the Evolution of Treatment in MCL

ByLuhua (Michael) Wang, MD

May 13th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Smith on Frontline Treatment Options in MCL

BySonali M. Smith, MD

May 13th 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Dr. Fenske on the Utility of Next-Generation BTK Inhibitors in MCL

ByTimothy Fenske, MD, MS

May 13th 2020

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCL

ByDiego Villa, MD, MPH

May 13th 2020

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Dr. Wang on the Evolution of Treatment in MCL

ByLuhua (Michael) Wang, MD

May 13th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

ByAndre Goy, MD, MS

May 12th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Gerson on Clinical Trial Accrual in MCL

ByJames N. Gerson, MD

May 12th 2020

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

ByAndre Goy, MD, MS

May 12th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Gerson on Clinical Trial Accrual in MCL

ByJames N. Gerson, MD

May 12th 2020

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

ByAndre Goy, MD, MS

May 11th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Smith on Safety Profiles of BTK Inhibitors in MCL

BySonali M. Smith, MD

May 11th 2020

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

ByAndre H. Goy, MD

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Goy on Comparing the Toxicity Profiles of BTK Inhibitors in MCL

ByAndre Goy, MD, MS

May 7th 2020

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Dr. Wang on the Results of the ZUMA-2 Trial in Relapsed/Refractory MCL

ByLuhua (Michael) Wang, MD

May 7th 2020

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision

ByDavid Miklos, MD, Stanford University

May 6th 2020

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

ByLuhua (Michael) Wang, MD

May 5th 2020

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL

ByDavid Miklos, MD, Stanford University

May 4th 2020

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.

MCL Treatments Step Away From Chemotherapy, Closer to a Cure

ByChristina T. Loguidice

April 24th 2020

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.

Dr. Villa on the Use of BR as Induction Therapy in MCL

ByDiego Villa, MD, MPH

April 8th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).

CAR T-Cell Therapy KTE-X19 Makes Waves in Relapsed/Refractory MCL

ByJessica Hergert

April 8th 2020

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.